CCK-B antagonists exhibit antidepressant-like effects and potentiate endogenous enkephalin analgesia. Correlation with in vivo binding affinities and brain penetration.
Durieux
C
C
Laboratoire de Pharmacochimie Moléculaire et Structurale, INSERM U 266-CNRS URA D 1500, Paris, France.
Derrien
M
M
Maldonado
R
R
Valverde
O
O
Blommaert
A
A
Fournié-Zaluski
M C
MC
Roques
B P
BP
D000818:Animals; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D001570:Benzodiazepinones / Q000494:pharmacology; D001812:Blood-Brain Barrier; D001921:Brain / Q000378:metabolism*; D002552:Cerebral Ventricles / Q000187:drug effects / Q000502:physiology*; D002766:Cholecystokinin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D004597:Electroshock; D007211:Indoles / Q000494:pharmacology; D007276:Injections, Intraventricular; D008536:Meglumine / Q000031:analogs & derivatives / Q000494:pharmacology; D051379:Mice; D009043:Motor Activity / Q000187:drug effects*; D010446:Peptide Fragments / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D010671:Phenylurea Compounds; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000928:Antidepressive Agents; C084553:BC 264; D001570:Benzodiazepinones; D007211:Indoles; D010446:Peptide Fragments; D010671:Phenylurea Compounds; D011949:Receptors, Cholecystokinin; C060186:BC 197; C065599:PD 134308; C058121:L 365260; D008536:Meglumine; D002766:Cholecystokinin